drugset / Trial / NCT06815471

CRF2 Agonist for the Treatment of Worsening Heart Failure

NCT06815471 ↗

Phase 2 Active not recruiting 300 enrolled Corteria Pharmaceuticals Worldwide Clinical Trials · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Timeline

Start
2025-08-07
Primary completion
2026-12
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject COR-1167 Peptide — —